I agree that this site is using cookies. You can find further informations here.
X
Arumí, Miriam
27  results:
Search for persons X
?
1

Patritumab deruxtecan in HER2-negative breast cancer: part ..:

Brasó-Maristany, Fara ; Ferrero-Cafiero, Juan Manuel ; Falato, Claudette...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
2

Observational study of HR+/HER2− metastatic breast cancer p..:

Blanch, Salvador ; Gil-Gil, Juan Miguel ; Arumí, Miriam...
Clinical and Translational Oncology.  25 (2023)  10 - p. 2950-2959 , 2023
Link: https://doi.org/10.1007/..
 
?
3

Treatment of mild asymptomatic cardiotoxicity in early-stag..:

Oristrell, Gerard ; Burcet, Gemma ; Valente, Filipa...
Revista Española de Cardiología (English Edition).  76 (2023)  6 - p. 480-483 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Pre-operative ribociclib plus letrozole versus chemotherapy..:

Villacampa, Guillermo ; Falato, Claudette ; Paré, Laia...
European Journal of Cancer.  174 (2022)  - p. 232-242 , 2022
Link: https://doi.org/10.1016/..
 
?
5

HER2-positive breast cancer: Current and new therapeutic st..:

Escrivá-de-Romaní, Santiago ; Arumí, Miriam ; Bellet, Meritxell.
The Breast.  39 (2018)  - p. 80-88 , 2018
Link: https://doi.org/10.1016/..
 
?
6

MET expression and copy number heterogeneity in nonsquamous..:

Casadevall, David ; Gimeno, Javier ; Clavé, Sergi...
Oncotarget.  6 (2015)  18 - p. 16215-16226 , 2015
Link: https://doi.org/10.18632..
 
?
7

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity ..:

Pascual, Tomás ; Oliveira, Mafalda ; Ciruelos, Eva...
Frontiers in Oncology.  11 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
8

MET expression and copy number heterogeneity in nonsquamous..:

Casadevall Aguilar, David ; Gimeno, Javier ; Clavé, Sergi...
Instituto de Salud Carlos III RD12-0036-0051.  , 2015
Link: https://ddd.uab.cat/reco..
 
?
9

Observational study of HR+/HER2− metastatic breast cancer p..:

Blanch, Salvador ; Gil Gil, Miguel J ; Arumí De Dios, Míriam...
Clinical and Translational Oncology;25.  , 2023
Link: https://hdl.handle.net/1..
 
?
10

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity ..:

Pascual, Tomás ; Antunes de Melo Oliveira, Ana Mafalda ; Ciruelos, Eva...
Frontiers in Oncology;11.  , 2021
Link: https://hdl.handle.net/1..
 
?
11

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity ..:

Pascual, Tomás ; Oliveira, Mafalda ; Ciruelos, Eva...
Reproducció del document publicat a: https://doi.org/10.3389/fonc.2021.638482.  , 2021
Link: http://hdl.handle.net/24..
 
?
12

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity ..:

Pascual, Tomás ; Oliveira, Mafalda ; Ciruelos, Eva...
2234-943X.  , 2021
Link: http://hdl.handle.net/10..
 
?
13

MET expression and copy number heterogeneity in nonsquamous..:

Casadevall Aguilar, David ; Gimeno Beltran, Javier ; Clavé Safont, Sergi...
Oncotarget. 2015 Jun 30;6(18):16215-26.  ,
Link: http://hdl.handle.net/10..
 
?
14

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity ..:

Tomás Pascual ; Mafalda Oliveira ; Eva Ciruelos...
https://www.frontiersin.org/articles/10.3389/fonc.2021.638482/full.  , 2021
Link: https://doi.org/10.3389/..
 
?
15

Cost-Effectiveness Analysis of Abrocitinib Compared with Ot..:

Romero Jiménez, Rosa María ; Herranz Pinto, Pedro ; Campos Domínguez, Minia...
PharmacoEconomics - Open.  8 (2024)  2 - p. 291-302 , 2024
Link: https://doi.org/10.1007/..
 
1-15